Do You Believe in the Growth Prospects of Soleno Therapeutics (SLNO)?

Group 1 - TimesSquare Capital Management's "U.S. Small Cap Growth Strategy" reported a gross return of 2.26% and a net return of 2.01% for Q3 2025, significantly underperforming the Russell 2000 Growth Index, which returned 12.19% [1] - All asset classes except fixed income outside the U.S. posted positive returns during the quarter [1] - The fund's top five holdings were highlighted as key investment picks for 2025 [1] Group 2 - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company that experienced a one-month return of -9.58% and a 52-week loss of 2.16%, with a market capitalization of $2.429 billion as of January 5, 2026 [2] - TimesSquare Capital added to its holdings in Soleno Therapeutics as shares pulled back by -19%, believing that allegations regarding the safety of its Vykat treatment for Prader-Willi Syndrome were inaccurate or exaggerated [3] - Soleno Therapeutics' net revenue more than doubled to $66 million in Q3 2025 compared to Q2 2025, with an increase in hedge fund interest from 52 to 58 portfolios [4]